Stanford Researchers Develop Injectable Cancer 'Vaccine' That Eliminates Tumors in Mice
Key Insights
Stanford University researchers have developed an injectable cancer (search) "vaccine" using two immune-stimulating agents that eliminated tumors in 87 of 90 mice when injected directly into one tumor site.
The treatment combines a CpG oligonucleotide (search) DNA fragment with an OX40 (search)-binding antibody to reactivate tumor-specific T cells, causing them to attack both treated and untreated metastases throughout the body.
A clinical trial testing the approach in 15 patients with low-grade lymphoma (search) has been launched, with one agent already approved for human use and the other previously tested in clinical trials.
Stanford University School of Medicine researchers have developed a novel injectable cancer (search) immunotherapy that eliminated tumors in mice by directly stimulating immune cells within the tumor microenvironment. The approach achieved remarkable success rates, curing 87 of 90 mice with lymphoma (search) when administered as a single injection into one tumor site.
Novel Two-Agent Approach
The treatment combines two immune-stimulating agents delivered in microgram quantities directly into solid tumors. The first agent, a CpG oligonucleotide (search), is a short stretch of DNA that works with nearby immune cells to amplify expression of the OX40 (search) activating receptor on T cell surfaces. The second component is an antibody that binds to OX40, activating the T cells to mount an attack against cancer (search) cells.
"When we use these two agents together, we see the elimination of tumors all over the body," said Ronald Levy, MD, professor of oncology and senior author of the study published in Science Translational Medicine. "This approach bypasses the need to identify tumor-specific immune targets and doesn't require wholesale activation of the immune system or customization of a patient's immune cells."
Mechanism and Systemic Effects
The treatment exploits a key characteristic of the tumor microenvironment. While T cells naturally infiltrate tumors and recognize abnormal cancer (search) proteins, growing tumors often suppress T cell activity. By injecting the two agents directly into the tumor, the approach reactivates only those T cells that have already been "prescreened" by the body to recognize cancer-specific proteins.
These activated, tumor-specific T cells then leave the original injection site to seek and destroy identical tumors throughout the body. In laboratory studies, treating one tumor site caused regression of both the treated tumor and distant, untreated metastases.
Broad Cancer Type Efficacy
The researchers demonstrated effectiveness across multiple cancer (search) types. In addition to the lymphoma (search) studies, the treatment showed similar results in mice bearing breast, colon, and melanoma (search) tumors. Mice genetically engineered to spontaneously develop breast cancers in all 10 mammary pads also responded to treatment, with therapy of the first tumor often preventing future tumor development and significantly extending lifespan.
To test specificity, researchers transplanted both lymphoma (search) and colon cancer (search) cells into mice. Treatment of the lymphoma site eliminated both lymphoma tumors but left colon cancer cells unaffected, demonstrating that the activated T cells remain specific to the original tumor type.
Clinical Translation Underway
A clinical trial launched in January is recruiting approximately 15 patients with low-grade lymphoma (search) to test the approach in humans. One of the two agents is already approved for human use, while the other has been tested in several unrelated clinical trials, potentially accelerating the path to clinical application.
The treatment offers several advantages over existing immunotherapy approaches. Unlike CAR T-cell therapy, which requires removing patient immune cells for genetic engineering, or systemic immune stimulation approaches that can cause significant side effects, this method uses local application of very small amounts of agents to stimulate immune cells only within the tumor itself.
Future Applications
Levy envisions the treatment being used prior to surgical tumor removal to prevent recurrence from unidentified metastases or lingering cancer (search) cells. The approach might also help prevent future tumors in patients with genetic mutations like BRCA1 and BRCA2.
"I don't think there's a limit to the type of tumor we could potentially treat, as long as it has been infiltrated by the immune system," Levy said.
The research represents a significant advance in cancer (search) immunotherapy, offering a potentially rapid and relatively inexpensive treatment option that could complement existing therapeutic approaches while avoiding many of their associated complications and costs.